Rallybio Corp (RLYB) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The company's lead program is RLYB116, a complement component 5 (C5) inhibitor. In Q3 2025, the company discontinued its RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) due to pharmacokinetic data failing to meet target concentrations. Additionally, the company sold its interest in the REV102 program (an ENPP1 inhibitor) to a subsidiary of Recursion Pharmaceuticals.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Total Revenue | $212 | $299 | $636 | $598 |
| Net Income (Loss) | $16,016 | $(11,466) | $(3,126) | $(46,731) |
| Operating Expenses | $7,137 | $12,365 | $27,288 | $49,486 |
| Research & Development | $4,143 | $8,240 | $15,942 | $34,122 |
| Cash & Cash Equivalents | $32,122 | $13,903 | $32,122 | $25,320 |
| Marketable Securities | $27,197 | $51,608 | $27,197 | $51,608 |
| Total Liquidity (Cash + Securities) | $59,319 | $65,511 | $59,319 | $76,928 |
Note: Q3 2025 Net Income includes a one-time gain of $22.479 million from the sale of the joint venture interest.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $16.0 million for Q3 2025, a reversal from a net loss of $11.5 million in Q3 2024. This is primarily driven by a $22.5 million gain on the sale of the joint venture (REV102) to Recursion Pharmaceuticals, which included $20.0 million in cash proceeds and $3.0 million in contingent consideration.
- Expense Reduction: Operating expenses decreased by 42% in Q3 2025 compared to Q3 2024 ($7.1M vs $12.4M). R&D expenses dropped significantly ($4.1M vs $8.2M) due to the discontinuation of the RLYB212 program and a 40% workforce reduction implemented in May 2025.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased to $59.3 million from $65.5 million in the prior year quarter, despite the $20 million inflow from the JV sale, due to operating cash burn and investment maturities.
Guidance, Outlook, and Risks
- Outlook: Management expects current liquidity ($59.3 million) to fund operations through 2027. The company anticipates reporting data from the RLYB116 confirmatory PK/PD trial in Q4 2025.
- Capital Needs: The company explicitly states it will require substantial additional capital to complete the development and commercialization of RLYB116. It has no committed external sources of funds.
- Key Risks:
- Delisting Risk: The company received a deficiency notice from Nasdaq in February 2025 for failing to meet the $1.00 minimum bid price. It transferred listing from the Global Select Market to the Nasdaq Capital Market in August 2025 and has until February 23, 2026, to regain compliance.
- Program Dependency: The business is heavily dependent on the success of RLYB116. The discontinuation of RLYB212 highlights the risk of clinical failure.
- Regulatory & Market: Risks include the unpredictability of clinical trial outcomes, regulatory approval processes, and the ability to raise capital in a volatile market.
Investor Verification Checklist
- Verify Liquidity Runway: Confirm the $59.3 million cash balance is sufficient to fund the RLYB116 confirmatory trial and subsequent Phase 2/3 studies through 2027 without immediate dilution.
- Assess One-Time Gain Impact: Analyze the sustainability of operations excluding the $22.5 million non-recurring gain from the JV sale, which masked an underlying operating loss.
- Monitor Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by the February 23, 2026 deadline to avoid delisting.
- Review RLYB116 Data: Await Q4 2025 data release from the confirmatory PK/PD trial to validate the improved tolerability and efficacy claims.
- Check Restructuring Costs: Verify the completion of the $1.7 million restructuring charges (severance) associated with the 40% workforce reduction.